2008 Articles
Genetic and phenotypic analysis of B-cell post-transplant lymphoproliferative disorders provides insights into disease biology
B‐cell post‐transplant lymphoproliferative disorders (PTLD) are classified as early lesions, polymorphic lymphomas (P‐PTLD) and monomorphic lymphomas (M‐PTLD). These morphologic categories are thought to reflect a biologic continuum, although supporting genetic data are lacking. To gain better insights into PTLD pathogenesis, we characterized the phenotypes, immunoglobulin (Ig) gene alterations and non‐Ig gene (BCL6, RhoH/TTF, c‐MYC, PAX5, CIITA, BCL7A, PIM1) mutations of 21 PTLD, including an IM‐like lesion, 8 P‐PTLD and 12 M‐PTLD. Gene expression profile analysis was also performed in 12 cases. All PTLD with clonal Ig rearrangements showed evidence of germinal centre (GC) transit based on the analysis of Ig and BCL6 gene mutations, and 74% had a non‐GC phenotype (BCL6 ± MUM1+). Although surface Ig abnormalities were seen in 6/19 (32%) PTLD, only three showed ‘crippling’ Ig mutations indicating other etiologies for loss of the B‐cell receptor. Aberrant somatic hypermutation (ASHM) was almost exclusively observed in M‐PTLD (8/12 vs. 1/8 P‐PTLD) and all three recurrent cases analysed showed additional mutations in genes targeted by ASHM. Gene expression analysis showed distinct clustering of PTLD compared to B‐cell non‐Hodgkin lymphomas (B‐NHL) without segregation of P‐PTLD from non‐GC M‐PTLD or EBV+ from EBV− PTLD. The gene expression pattern of PTLD appeared more related to that of memory and activated B‐cells. Together, our results suggest that PTLD represent a distinct type of B‐NHL deriving from an antigen experienced B‐cell, whose evolution is associated with accrual of genetic lesions.
Files
- Vakiani E et al., Hematol Oncol 2008.pdf application/pdf 242 KB Download File
Also Published In
- Title
- Hematological Oncology
- DOI
- https://doi.org/10.1002/hon.859
More About This Work
- Academic Units
- Institute for Cancer Genetics
- Pathology and Cell Biology
- Published Here
- November 27, 2019